Skip to main content
. 2024 Jul 11;16(7):922. doi: 10.3390/pharmaceutics16070922

Table 3.

Determination of the minimum inhibitory concentration (MIC, mg/mL−1) of NLC formulations against Campylobacter ssp. strains (n = 3).

Strains
Samples
131/5
C. coli **
131/6
C. coli **
131/7
C. coli **
30/1
C. jejuni **
64/5
C. jejuni **
34,763/3
C. jejuni **
F1 00.23 ± 0.00 00.23 ± 0.00 00.23 ± 0.00 00.23 ± 0.00 24.51 ± 8.49 00.23 ± 0.00
F2 00.23 ± 0.00 00.23 ± 0.00 00.23 ± 0.00 00.23 ± 0.00 01.53 ± 0.53 00.23 ± 0.00
F3 00.20 ± 0.00 00.20 ± 0.00 00.20 ± 0.00 00.23 ± 0.00 39.47 ± 22.79 00.20 ± 0.00
F4 00.20 ± 0.00 00.20 ± 0.00 13.16 ± 0.00 00.47 ± 3.31 * 00.20 ± 0.00
F5 00.26 ± 0.11 00.19 ± 0.00 00.78 ± 0.00 00.19 ± 0.00 04.16 ± 1.81 00.19 ± 0.00
F6 03.33 ± 3.97 00.32 ± 0.14 >62.50 ± 0.00 52.08 ± 18.04 * 10.66 ± 17.8
F7 39.21 ± 16.98 29.41 ± 0.00 39.21 ± 16.98 * * 29.41 ± 0.00
F8 13.16 ± 0.00 13.16 ± 0.00 >52.63 ± 0.00 * * 26.32 ± 0.00

Note: F1, lemongrass EO and mumururu butter; F2, cinnamon EO and cocoa butter; F3, geranium EO and beeswax; F4, clove EO and cocoa butter; F5, oregano EO and beeswax; F6, mururumu butter; F7, cocoa butter; and F7, beeswax. All the formulations had poloxamer as a surfactant. * No inhibition. ** p < 0.05.